文献速递心外重症与机械循环支持

HeartMate 3左心室辅助装置植入后早期右心衰竭:危险因素与结局

Early right ventricular failure following HeartMate 3 left ventricular assist device implantation: Risk factors and outcomes.
PubMed 文献 · J Heart Lung Transplant · 2026-03-26

基于MOMENTUM 3试验中2200例HM3受体,按2020 MCS-ARC标准将患者分为早期右心衰竭组与无早期右心衰竭组。402例(18.3%)发生早期右心衰竭,其中141例(6.4%)需RVAD支持。早期右心衰竭与2年生存率降低独立相关(aHR 3.3,95%CI 2.7-4.1),需RVAD者结局最差。

要点

  • HM3受体早期右心衰竭发生率为18.3%,其中6.4%需RVAD支持。
  • 早期右心衰竭是2年死亡率的强独立预测因子(aHR 3.3,95%CI 2.7-4.1)。
  • 需RVAD者2年生存率仅44.7%,结局最差。

核心结论

  • 早期右心衰竭是HM3受体不良结局的强预测因子。
  • 需RVAD支持的右心衰竭患者2年生存率最低。

研究设计与样本

  • 分析MOMENTUM 3试验(随机IDE和继续访问协议)中所有HM3受体,共2200例。
  • 按2020 MCS-ARC标准将患者分为早期右心衰竭组与无早期右心衰竭组,严重右心衰竭定义为需RVAD。
  • 主要结局为2年总生存率和无致残性卒中或装置交换的生存率,Cox模型校正年龄、性别、治疗目标及INTERMACS分级。

主要发现

  • 402例(18.3%)发生早期右心衰竭,其中141例(6.4%)需RVAD支持。
  • 早期右心衰竭组2年生存率62.0% vs 84.6%(p<0.001),无致残性卒中或装置交换生存率56.8% vs 80.3%(p<0.001)。
  • 多变量校正后,早期右心衰竭仍为死亡的独立预测因子(aHR 3.3,95%CI 2.7-4.1)和复合终点的独立预测因子(aHR 2.95,95%CI 2.4-3.6)。
  • 需RVAD者2年生存率44.7%(HR 5.3,95%CI 4.1-6.8;p<0.001)。
  • 基线时早期右心衰竭患者更可能有显著三尖瓣反流、较高血清肌酐(p<0.001)及较高右心房压与肺毛细血管楔压比值。

关键数值与推荐

  • 早期右心衰竭按2020 MCS-ARC标准定义。
  • 严重右心衰竭定义为需右心室辅助装置(RVAD)支持。

临床怎么用

  • 应重视HM3植入后早期右心衰竭的预防、识别和积极管理,以充分利用装置技术改进。
  • 对具有显著三尖瓣反流、较高血清肌酐及较高右心房压与肺毛细血管楔压比值的患者,需警惕早期右心衰竭风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Right ventricular failure (RVF) remains a major determinant of early morbidity and mortality after left ventricular assist device (LVAD) implantation. The long-term consequences of early RVF in contemporary HM3 recipients remain incompletely characterized. METHODS: We analyzed all HM3 recipients enrolled in the MOMENTUM 3 trials, including the randomized investigational device exemption and the continued access protocol. Patients were stratified by presence or absence of early RVF, according to the 2020 MCS-ARC criteria. Severe RVF was defined as need for right ventricular assist device (RVAD). Primary outcomes were 2-year overall survival and survival free of disabling stroke or device exchange. Cox models were adjusted for age, sex, goal of therapy, and INTERMACS profile. RESULTS: Among 2200 HM3 patients, 402 (18.3%) developed early RVF, including 141 (6.4%) who required RVAD support. At baseline, patients with early RVF were more likely to have significant tricuspid regurgitation, higher serum creatinine (p<0.001), and higher right atrial pressure to pulmonary capillary wedge pressure ratio. Early RVF was associated with lower 2-year survival (62.0% vs 84.6%; p<0.001) and lower survival free of disabling stroke or device exchange (56.8% vs 80.3%; p<0.001). After multivariable adjustment, early RVF remained a strong independent predictor of mortality (aHR 3.3, 95% CI 2.7-4.1) and the composite endpoint (aHR 2.95, 95% CI 2.4-3.6). Patients requiring RVAD had the worst outcomes, with 2-year survival of 44.7% (HR 5.3, 95% CI 4.1-6.8; p<0.001). CONCLUSIONS: Early RVF is a powerful predictor of adverse outcomes in HM3 recipients. Development of strategies to prevent, identify, and aggressively manage RVF is essential to fully leverage improvements made in device technology. TRIAL REGISTRATION: Momentum 3 portfolio, NCT02224755 (Pivotal) and NCT02892955 (CAP).

来源:J Heart Lung Transplant,查看原文。版权归原作者所有。

引用

  1. Sayer G, Elad B, Goldstein D, et al. Early right ventricular failure following HeartMate 3 left ventricular assist device implantation: Risk factors and outcomes. J Heart Lung Transplant. 2026. PMID: 41903627. doi:10.1016/j.healun.2026.03.025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。